[{"id":"1e7d842e-e4ca-4d95-b896-1da6f52d2d98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03726515","created_at":"2021-01-18T18:15:36.195Z","updated_at":"2024-07-02T16:35:44.942Z","phase":"Phase 1","brief_title":"CART-EGFRvIII + Pembrolizumab in GBM","source_id_and_acronym":"NCT03726515","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • LXF821"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 02/27/2021","primary_completion_date":" 02/27/2021","study_txt":" Completion: 02/27/2021","study_completion_date":" 02/27/2021","last_update_posted":"2023-06-22"}]